Genmab — Februar 2018
-
En ældre Plesner sag: Daratumumab has been shown to have synergistic antitumor activity in combination with lenalidomide in vitro through the activation of effector cells. Interestingly, CD38 upregulation has been reported with IMiDs, including lenalidomide, which supports the rationale for combining these agents in MM. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054695/
-
Men Plesner har tidligere udtalt skepsis ved på denne måde at øge cd38 udtrykket https://www.youtube.com/watch?v=RUpfj1PskPM
-
Tænker du på denne her https://ash.confex.com/ash/2017/webprogram/Paper105329.html
-
SeaGen, Pieris ink deal for bispecific I/O drugs https://www.biopharmadive.com/news/seagen-pieris-ink-deal-for-bispecific-io-drugs/516764/
-
Expert Highlights Early Promise of Selinexor in Myeloma http://www.onclive.com/web-exclusives/expert-highlights-early-promise-of-selinexor-in-myeloma
-
God morgen.

-
Tak Vitus. Er på arbejde alle ugens 7 dage. Derfor har jeg også morgenhilsen på søndage.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
Både pga af CAR-T prissætning og deres betydelige indtægtskilde i Revlimid.